Spago on the increased dose in Tumorad-01

2 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In March, Spago Nanomedical announced that the independent Data Monitoring Committee had recommended a dose escalation in the ongoing phase I/IIa study with the company’s cancer drug candidate. This marks an important step in the study, which Paul Hargreaves, CDO at Spago Nanomedical, discusses further in an interview with BioStock.

0:00 Intro
0:30 Tumorad-01
1:07 Data behind dose increase
1:47 Why is the increase significant?
2:12 Timeline
2:46 How does the study help treatment planning?
3:34 Key objectives of next study phase
4:09 Feedback from clinical sites

Subscribe and follow BioStock on:
YouTube https://bit.ly/Biostock
LinkedIn: https://www.linkedin.com/company/biostock
Facebook: https://www.facebook.com/biostock.se

https://www.biostock.se/
#BioStock #LifeScience #SpagoNanomedical
Category
Oncology
Be the first to comment

Up Next